WuXi AppTec and Cyclica to collaborate on drug discovery efforts

Handshake business deal executives
The multiphase collaboration is also designed to help drive Cyclica’s biophysics and AI-supported platform. (Pixabay)

WuXi AppTec’s research service division and Canadian biotech Cyclica announced a partnership to develop programs looking into the development of small molecule polypharmacology.

The multiphase collaboration is also designed to help drive Cyclica’s biophysics and AI-supported platform, the two said.

WuXi will be looking specifically at how to leverage Cyclica’s cloud-based proteome Ligand Express screening platform as well as using Cyclica’s AI tech for predictive models for ADMET properties. The Chinese R&D company will also support the testing and optimization of Cyclica’s next generation of AI-based de novo drug design technology.

Sponsored by Clinical Ink

White Paper: Keep Your GI Trials Moving During COVID-19

Clinical Ink’s intimate knowledge of and experience with GI trials enables a better deployment experience and improved trial conduct. Learn how our GI-specific data capture solutions can support virtual and hybrid trials during COVID-19.

“What makes Cyclica’s value proposition unique is that they offer enabling solutions at various points across the value chain which we believe will help us take further steps in the right direction,” Dave Madge, vice president of WuXi’s research services division, said in a statement. “We are excited to apply, evaluate and support the growth of their technologies, and assess how they fit in our overall strategy to advance preclinical success.”

RELATED: WuXi AppTec to test AI-generated compounds from Insilico Medicine

Cyclica’s chief executive, Naheed Kurji, added that the partnership will allow Cyclica to advance its efforts to provide researchers with a platform built around a network of technologies that will support the design, screening and stratification of improved drugs.

Suggested Articles

The National Institute of Allergy and Infectious Diseases is launching a new clinical trials network for COVID-19.

In a mix-up of trial-based solutions, CRO Parexel is using its recent partnership with Datavant to run a pact with life science data firm TriNetX.

With stints at Genzyme, Bayer and, most recently, TranScrip Partners, Gilbert Wagener, M.D., Ph.D., is now signing up to U.K. biotech Rexgenero.